DGAP-News

PharmaSGP: Revenue growth in 2020 despite declining markets - Seite 3

In 2021, the further course of the Covid-19 pandemic is a key factor for the performance of PharmaSGP. Based on the continued lockdown situations and current signs of a strong third wave of infections, PharmaSGP does not anticipate a general economic recovery in the first two quarters of 2021. Looking at the relevant European OTC markets, PharmaSGP expects year-on-year growth in the second half of the year at the earliest. Against this background, the Management Board forecasts total revenue of between €56 million and €60 million for 2021, with stable to slightly positive development of the 'Health Brands' category and an expected decline in the 'Beauty' business. The adjusted EBIT margin is expected to increase to 27-30%. The forecast does not take into account possible acquisitions.

PharmaSGP will publish its full statement for the 2020 financial year on 22 April 2021, in the 'Publications' section of the company's website ir.sgp-pharma.com.

OVERVIEW OF PRELIMINARY FIGURES, YEAR-ON-YEAR COMPARISON

Group key figures (in € million)	2019	2020	∆
Revenues	62.6	63.2	1.1%
Adjusted1 EBIT	22.4	16.5	-26.3%
Unadjusted EBIT	22.4	14.2	-36.4%
Adjusted1 EBIT margin	35.8%	26.1%
Unadjusted EBIT margin	35.8%	22.5%
Revenues by region (in € million)	2019	2020	∆
Germany	45.8	43.4	-5.3 %
Italy	7.4	8.8	19.8 %
Other European countries	9.4	11.0	17.7 %
Share of revenues by region	2019	2020
Germany	73.2%	68.6%
Italy	11.8%	14.0%
Other European countries	15.0%	17.4%
Revenues by product category (in € million)	2019	2020	∆
Health Brands	49.0	54.8	11.8%
Beauty Brands	13.0	8.4	-35.2%

 

^[1] The one-off costs and special effects amount to €2.3 million and include, among other things, costs of the corporate and organizational structuring of the PharmaSGP Group as well as legal and consulting costs in connection with planned acquisitions.